BCM
CRNX icon

BlueCrest Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

BlueCrest Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,289
Closed -$381K – 964
2018
Q3 		$381K Buy
+13,289
New +$395K 0.01% 905

Other funds holding CRNX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlueCrest Capital Management's CRNX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2018, closing a stake of 13,289 shares — an estimated $381K sold.

BlueCrest Capital Management first reported a position in CRNX in Q3 2018 and held it in 1 quarter. The position peaked at $381K in Q3 2018. 50 funds tracked by Wall St. Rank hold CRNX as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 13,289 Crinetics Pharmaceuticals shares in Q4 2018, an estimated $381K.
  • BlueCrest Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Crinetics Pharmaceuticals position peaked at $381K in Q3 2018.
  • 50 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.